Login to Your Account

BioSpain 2012

Zeltia Group's Success May Energize Spanish Biotechs

By Cormac Sheridan
Staff Writer

Wednesday, September 26, 2012
BILBAO, Spain – The coming months will be a crucial period in the development of Zeltia Group, Spain's flagship biotechnology company, which is due to report data from several clinical trials, including a Phase IIb trial of Nypta (tideglusib) in Alzheimer's disease and a Phase III trial of Aplidin (ptilidepsin) in multiple myeloma.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription